MCK
McKesson Corporation
$860.44
장중 · Vol 34.6K · 52주 $682.35–$999.00 · 기준 2026. 8. 21. PM 3:59 ET
일봉 $881.27 · Aug 31, 2026
MCK 가격 추세
종가
$881.27
시가
$882.83
고가
$887.35
저가
$876.48
30초 브리핑
MCK 오늘의 판단 요약
보유 데이터를 비교 가능한 문장으로 해석한 요약입니다.
52주 범위의 56%
52주 범위 중간 구간으로 가격 위치만으로 방향성은 제한적입니다.
Forward P/E 17.5배
선행 P/E가 낮아 시장은 이익 증가를 반영하고 있습니다.
20일 평균의 1.3배
거래량은 최근 평균 범위입니다.
2026-11-04
실적 전후 변동성 확대 가능성이 있으므로 컨센서스 범위와 옵션 기대변동을 함께 보세요.
펀더멘털 기준 Sep 1, 2026 · 규칙 기반 요약이며 투자 조언이 아닙니다.
핵심 통계
MCK 일봉·펀더멘털 스냅샷 기준 주요 지표
펀더멘털 스냅샷 Sep 1, 2026
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services for manufacturers. It also provides consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies; gene therapy with InspiroGene, practice consulting, and vaccine distribution services; and technology solutions, as well as research, insights, technologies, and services to improve cancer and specialty care. In addition, the company helps in solving medication access, affordability, and adherence challenges for patients by working across healthcare to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies. Further, it offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, patient enrollment, third-party logistics, and wholesale distribution support; medical-surgical supplies, laboratory equipment, pharmaceutical distribution, logistics, and other services to healthcare providers, including physician offices, surgery centers, and hospital reference labs, nursing homes, hospice and home health care agencies, government facilities ,and online marketplaces and retailers. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
6555 State Highway 161 · Irving, TX, United States · 직원 41,600명
시가총액
$103.22B
Trailing P/E
24.0
최근 12개월 이익 기준
Forward P/E
17.5
이익 증가 기대 반영
EPS (TTM)
$36.92
배당 수익률
0.42%
배당성향
8.8%
베타
0.31
시장보다 방어적
ROE
—
P/B
-24.22
EV/EBITDA
16.1
52주 범위
$682.35 – $999.00
현재 위치 56%
거래량
835.9K
20일 평균 647.7K · 1.3배
애널리스트 의견
매수 78%
총 18명 · 0m
DITM LEAPS Analysis
MCK 장기 DITM 콜옵션을 진입 적합도 순으로 비교
| Contract | Expiry | Strike | Price | Lev. | Delta | Extrinsic | Spread | IV | OI | Score | 상세 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MCK280121C00710000 | 1/21/28 · 1.4Y | $710.00 | $187.50 | 4.3x | 0.9100 | 6.5% | 4.80% | 19.61% | 19 | 80.18 | |
| MCK280121C00530000 | 1/21/28 · 1.4Y | $530.00 | $385.00 | 2.1x | 0.9072 | 7.7% | 2.60% | 46.54% | 12 | 68.40 | |
| MCK280121C00500000 | 1/21/28 · 1.4Y | $500.00 | $421.50 | 1.9x | 0.9117 | 8.6% | 2.14% | 51.25% | 11 | 67.36 | |
| MCK280121C00630000 | 1/21/28 · 1.4Y | $630.00 | $285.00 | 2.7x | 0.8824 | 10.4% | 3.51% | 34.81% | 1 | 64.62 | |
| MCK280121C00540000 | 1/21/28 · 1.4Y | $540.00 | $387.50 | 2.0x | 0.8903 | 10.9% | 2.32% | 50.90% | 6 | 61.53 | |
| MCK280121C00550000 | 1/21/28 · 1.4Y | $550.00 | $378.50 | 2.1x | 0.8866 | 11.4% | 2.38% | 50.00% | 9 | 61.31 | |
| MCK280121C00750000 | 1/21/28 · 1.4Y | $750.00 | $171.50 | 4.3x | 0.8265 | 21.1% | 5.25% | 24.31% | 15 | 60.54 | |
| MCK280121C00560000 | 1/21/28 · 1.4Y | $560.00 | $370.50 | 2.1x | 0.8817 | 12.2% | 2.43% | 49.53% | 5 | 59.61 | |
| MCK280121C00600000 | 1/21/28 · 1.4Y | $600.00 | $337.50 | 2.3x | 0.8623 | 15.5% | 2.67% | 47.11% | 9 | 56.18 | |
| MCK280121C00610000 | 1/21/28 · 1.4Y | $610.00 | $329.50 | 2.3x | 0.8570 | 16.4% | 2.73% | 46.57% | 14 | 55.49 | |
| MCK280121C00650000 | 1/21/28 · 1.4Y | $650.00 | $289.00 | 2.6x | 0.8423 | 18.6% | 3.46% | 41.52% | 17 | 54.50 | |
| MCK280121C00700000 | 1/21/28 · 1.4Y | $700.00 | $262.50 | 2.7x | 0.8008 | 29.4% | 2.67% | 42.47% | 12 | 42.77 | |
| MCK280121C00720000 | 1/21/28 · 1.4Y | $720.00 | $239.00 | 2.9x | 0.7918 | 30.8% | 4.18% | 39.32% | 0 | 39.79 | |
| MCK280121C00730000 | 1/21/28 · 1.4Y | $730.00 | $233.00 | 3.0x | 0.7833 | 33.3% | 4.29% | 39.26% | 3 | 38.62 | |
| MCK280121C00740000 | 1/21/28 · 1.4Y | $740.00 | $234.50 | 2.9x | 0.7711 | 38.0% | 2.99% | 40.91% | 28 | 36.44 | |
| MCK280121C00760000 | 1/21/28 · 1.4Y | $760.00 | $221.50 | 3.0x | 0.7550 | 43.4% | 3.16% | 40.29% | 1 | 28.90 |
재무제표
MCK 연간 손익·현금흐름·재무상태
매출 성장률
+12.4%
최근 연간 YoY
EPS 성장률
+49.2%
최근 연간 YoY
영업이익률
1.6%
최근 연간
FCF 마진
1.3%
잉여현금흐름 / 매출
매출 추세
순이익 추세
잉여현금흐름 추세
| 항목 | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| 매출 | $403.43B+12.4% | $359.05B+16.2% | $308.95B+11.7% | $276.71B |
| 매출총이익 | $14.55B+9.2% | $13.32B+3.9% | $12.83B+3.8% | $12.36B |
| 영업이익 | $6.45B+34.0% | $4.82B+15.5% | $4.17B-9.0% | $4.58B |
| 순이익 | $4.76B+44.5% | $3.29B+9.8% | $3.00B-15.7% | $3.56B |
| 희석 EPS | $38.38+49.2% | $25.72+14.9% | $22.39-10.5% | $25.03 |
| EBITDA | $7.18B+36.4% | $5.26B+12.5% | $4.68B-14.8% | $5.49B |
| 영업현금흐름 | $6.16B+1.2% | $6.08B+41.1% | $4.31B-16.4% | $5.16B |
| 잉여현금흐름 | $5.41B+3.5% | $5.23B+44.1% | $3.63B-21.2% | $4.60B |
| 총자산 | $82.32B+9.6% | $75.14B+11.4% | $67.44B+8.2% | $62.32B |
| 총부채 | $8.61B+16.6% | $7.39B+0.0% | $7.39B+1.3% | $7.29B |
최신 연도 우선 · 작은 퍼센트는 직전 연도 대비 변화입니다.
캘린더
MCK 실적·배당 일정
매출 하단
$108.81B
EPS 하단
$10.53
매출 상단
$110.79B
배당 지급일
2026-10-01
D-30
실적 발표일
2026-11-04
D-64
EPS 상단
$11.26
매출 컨센서스
$109.93B
EPS 컨센서스
$10.76
배당락일
2026-09-01
오늘
최근 배당
| 배당락일 | 주당 배당 |
|---|---|
| Jun 1, 2026 | $0.8200 |
| Mar 2, 2026 | $0.8200 |
| Dec 1, 2025 | $0.8200 |
| Sep 2, 2025 | $0.8200 |
| Jun 2, 2025 | $0.7100 |
| Mar 3, 2025 | $0.7100 |
| Dec 2, 2024 | $0.7100 |
| Aug 30, 2024 | $0.7100 |
뉴스
MCK 관련 최신 기사
실적AbbVie vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie trades cheaper but carries heavy revenue concentration; Johnson & Johnson boasts a fortress balance sheet and wider portfolio.
Motley Fool · Aug 29, 2026
- 실적
Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.
Motley Fool · Aug 29, 2026
M&AMcKesson Corporation (MCK) Doubles Down on Healthcare Growth With Precision Medicine Acquisition
McKesson Corporation (NYSE:MCK) has agreed to acquire privately held Precision Medicine Group for approximately $2.25 billion, as the healthcare company continues shifting its portfolio toward higher-growth businesses. Precision Medicine provides clinical research, laboratory testing, and commercialization services to biotechnology and pharmaceutical companies developing and launching new medicines. McKesson plans to integrate the company into its […]
Insider Monkey · Aug 29, 2026
M&AWhat Does McKesson (MCK) Gain From Its Push Into Oncology And Clinical Research?
McKesson (NYSE:MCK) announced an agreement to acquire Precision Medicine Group to expand its oncology and clinical research services. The deal is aimed at deepening McKesson's role in personalized medicine and specialty care, particularly in oncology and biopharma clinical trial support. The acquisition is expected to reshape McKesson's service mix across oncology practices, biopharma partners and clinical research organizations. For readers looking beyond McKesson to other potential...
Simply Wall St. · Aug 27, 2026
M&AMcKesson to Acquire Precision Medicine Group to Strengthen Services
MCK's $2.25B Precision Medicine Group deal aims to expand clinical research and commercialization services in oncology and multispecialty care.
Zacks · Aug 27, 2026
- 일반
Zepbound may cut healthcare costs, study says; Summit, Akeso drug hits in another China trial
A real-world study suggests Zepbound use could reduce the rates of hospital stays and ER visits. Elsewhere, McKesson sprung for a multibillion-dollar deal and J&J nabbed a noteworthy approval.
BioPharma Dive · Aug 26, 2026
M&AMcKesson to acquire Precision Medicine Group for $2.25bn
McKesson believes that the deal will support its clinical research and biopharmaceutical commercialisation services.
Pharmaceutical Technology · Aug 26, 2026
일반Update: Equities Rise Despite US-Canada Trade Tensions
(Updates with market moves at the end of the day, and other changes, if any.) Stocks rose Tuesday
MT Newswires · Aug 25, 2026
- 일반
Sector Update: Healthcare Stocks Advance Late Afternoon
Healthcare stocks rose late Tuesday afternoon with the NYSE Healthcare Index and the State Street He
MT Newswires · Aug 25, 2026
일반Update: Equities Rise Intraday, Oil Falls as Markets Monitor Trade Developments
(Updates with latest market prices and developments.) US benchmark equity indexes were higher int
MT Newswires · Aug 25, 2026
홀더
MCK 내부자·기관 보유 현황
최신 보고 목록 기준이며 실제 거래 시점과 보고일 사이에는 시차가 있습니다.
기관 보유
93.6%
기관 보유 (유동주식)
93.6%
내부자 보유
0.1%
기관 수
2,673
주요 기관 홀더
| 홀더 | 주식 수 | 평가액 | 지분 | 변동 | 보고일 |
|---|---|---|---|---|---|
| Blackrock Inc. | 10.80M | $9.56B | 9.3% | -5.5% | Jun 30, 2026 |
| Vanguard Capital Management LLC | 7.85M | $6.95B | 6.7% | -1.4% | Jun 30, 2026 |
| State Street Corporation | 5.73M | $5.07B | 4.9% | -0.1% | Jun 30, 2026 |
| Morgan Stanley | 5.31M | $4.70B | 4.6% | 130.7% | Jun 30, 2026 |
| Franklin Resources, Inc. | 2.91M | $2.57B | 2.5% | -5.2% | Jun 30, 2026 |
| Vanguard Portfolio Management LLC | 2.87M | $2.54B | 2.5% | -0.3% | Jun 30, 2026 |
| Geode Capital Management, LLC | 2.82M | $2.50B | 2.4% | -2.8% | Jun 30, 2026 |
| Massachusetts Financial Services Co. | 2.45M | $2.17B | 2.1% | -15.7% | Jun 30, 2026 |
| FMR, LLC | 2.13M | $1.89B | 1.8% | -40.9% | Jun 30, 2026 |
| JPMORGAN CHASE & CO | 1.75M | $1.55B | 1.5% | -46.5% | Jun 30, 2026 |
면책조항: 증시가격은 모든 주식 시장의 최신 증시가격을 표시하는 것은 아니며, 정보가 지연되거나 잘못될 수 있습니다. 거래 목적이나 조언이 아닌 정보 제공 목적으로만 제공됩니다.